226 related articles for article (PubMed ID: 34168046)
1. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.
Koh SB; Ross K; Isakoff SJ; Melkonjan N; He L; Matissek KJ; Schultz A; Mayer EL; Traina TA; Carey LA; Rugo HS; Liu MC; Stearns V; Langenbucher A; Saladi SV; Ramaswamy S; Lawrence MS; Ellisen LW
Clin Cancer Res; 2021 Sep; 27(17):4883-4897. PubMed ID: 34168046
[TBL] [Abstract][Full Text] [Related]
2. RASAL2 activates RAC1 to promote triple-negative breast cancer progression.
Feng M; Bao Y; Li Z; Li J; Gong M; Lam S; Wang J; Marzese DM; Donovan N; Tan EY; Hoon DS; Yu Q
J Clin Invest; 2014 Dec; 124(12):5291-304. PubMed ID: 25384218
[TBL] [Abstract][Full Text] [Related]
3. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
4. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
5. PRKAA/AMPKα phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy.
Bao Y; Qian C; Liu MY; Jiang F; Jiang X; Liu H; Zhang Z; Sun F; Fu N; Hou Z; Ke Y; Li Y; Qian ZM
Autophagy; 2021 Nov; 17(11):3607-3621. PubMed ID: 33563064
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expression.
Guo L; Zheng J; Zhang J; Wang H; Shao G; Teng L
Oncol Rep; 2016 Aug; 36(2):729-36. PubMed ID: 27373987
[TBL] [Abstract][Full Text] [Related]
7. MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC.
Franklin DA; Sharick JT; Ericsson-Gonzalez PI; Sanchez V; Dean PT; Opalenik SR; Cairo S; Judde JG; Lewis MT; Chang JC; Sanders ME; Cook RS; Skala MC; Bordeaux J; Orozco Bender J; Vaupel C; Geiss G; Hinerfeld D; Balko JM
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634121
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
9. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
10. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
[TBL] [Abstract][Full Text] [Related]
11. Low Expression of Rasal2 Promotes Non-small Cell Lung Cancer Metastasis through Ras/ERK Pathway.
Fan D; Yu S; Yang Y; Qu S
Biol Pharm Bull; 2021; 44(7):992-998. PubMed ID: 34193694
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
13. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
14. An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer.
van der Noord VE; McLaughlin RP; Smid M; Foekens JA; Martens JWM; Zhang Y; van de Water B
Sci Rep; 2019 Sep; 9(1):13308. PubMed ID: 31527768
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
18. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
20. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
